Cargando…

PB2156: ANALYSIS OF POSSIBLE CLONAL ORIGIN OF LARGE B-CELL DIFFUSED LYMPHOMAS ARISING IN PATIENTS WITH PRE-EXISTING HODGKIN’S LYMPHOMA

Detalles Bibliográficos
Autores principales:	Masciopinto, P., Bellitti, E., Opinto, G., Arcuti, E., Mastracci, L., Ciavarella, S., Cazzato, G., Guarini, A., Maiorano, E., Musto, P., Ingravallo, G., Gaudio, F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431574/ http://dx.doi.org/10.1097/01.HS9.0000851452.54269.c9

Ejemplares similares

Diffuse Large B Cell Lymphoma Arising in Patients with Preexisting Hodgkin Lymphoma
por: Bellitti, Emilio, et al.
Publicado: (2022)

Hodgkin Lymphoma: A Special Microenvironment
por: Opinto, Giuseppina, et al.
Publicado: (2021)

Molecular Features and Diagnostic Challenges in Alpha/Beta T-Cell Large Granular Lymphocyte Leukemia
por: Gaudio, Francesco, et al.
Publicado: (2022)

The Tumor Microenvironment in Classic Hodgkin’s Lymphoma in Responder and No-Responder Patients to First Line ABVD Therapy
por: Tamma, Roberto, et al.
Publicado: (2023)

PB2156: CLINICAL AND PROGNOSTIC FACTORS IN MULTIPLE MYELOMA IN THE GOMEL REGION
por: Kozich, Zhanna, et al.
Publicado: (2023)

The Effect of the Tumor Microenvironment on Lymphoid Neoplasms Derived from B Cells
por: Ingravallo, Giuseppe, et al.
Publicado: (2022)

P1084: CHECK-POINT INHIBITORS IN PATIENTS WITH RELAPSE/REFRACTORY HODGKIN’S LYMPHOMA: A RETROSPECTIVE ANALYSYS BY THE RETE EMATOLOGICA PUGLIESE (REP).
por: Gaudio, F., et al.
Publicado: (2022)

PB2062: EPIDEMIOLOGICAL, CLINICAL AND THERAPEUTIC FEATURES OF REFRACTORY HODGKIN’S LYMPHOMA.
por: Ben Sghaier, R., et al.
Publicado: (2022)

PB2435: ALLOGENEIC STEM CELL TRANSPLANTATION OUTCOMES IN HODGKIN LYMPHOMA: A PROGNOSTIC STUDY OF 30 PATIENTS WITH RELAPSED AND REFRACTORY HODGKIN LYMPHOMA
por: Zamani, Shayan, et al.
Publicado: (2023)

PB2155: B-CELL NON-HODGKIN’S LYMPHOMAS ASSOCIATED WITH AMYLOIDOSIS
por: Navrátilova, M., et al.
Publicado: (2022)

PB2064: RELAPSED/REFRACTORY HODGKIN LYMPHOMA PATIENTS TREATED WITH RADIOTHERAPY
por: Kallel, F., et al.
Publicado: (2022)

PCR clonality detection in Hodgkin lymphoma
por: Hebeda, K. M., et al.
Publicado: (2009)

PB2256: EPIDEMIOLOGY AND OUTCOMES OF HODGKIN LYMPHOMA IN URUGUAY. A NATIONAL REGISTRY
por: Oliver, Carolina, et al.
Publicado: (2023)

PB2321: THE EFFECT OF PRE-TREATMENT SERUM KINDLIN-3 ON HODGKIN AND NON-HODGKIN LYMPHOMAS: A SINGLE CENTER EXPERIENCE
por: Keskin, Melike, et al.
Publicado: (2023)

PB2282: HERPESVIRUSES REPLICATION DURING COVID-19 IN NON-HODGKIN’S LYMPHOMA PATIENTS.
por: Sychevskaya, K., et al.
Publicado: (2022)

PB2383: MICROSATELLITE INSTABILITY AND 9P24.1 ALTERATIONS IN HODGKIN LYMPHOMA
por: Tregubova, Ekaterina, et al.
Publicado: (2023)

PB2160: ASSOCIATION OF BCL-2 EXPRESSING TUMOR CELLS WITH RESPONSE TO FRONTLINE CHEMOTHERAPY IN NODULAR SCLEROSIS HODGKIN LYMPHOMA
por: Diakonov, D., et al.
Publicado: (2022)

PB2178: OUTCOMES OF REDUCED DOSE TEAM (THIOTEPA, ETOPOSIDE, CYTARABINE, MELPHALAN) PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION FOR HODGKIN AND NON-HODGKIN LYMPHOMA: A MONOCENTRIC EXPERIENCE
por: Di Folca, S., et al.
Publicado: (2022)

PB2263: TOXICITY PROFILE OF SALVAGE CHEMOTHERAPY REGIMENS IN PATIENTS WITH RELAPSED/ REFRACTORY HODGKIN LYMPHOMA.
por: Zahra, Kmira, et al.
Publicado: (2023)

PB2255: ASSESSMENT OF CHEMOTHERAPY-INDUCED TOXICITY IN CHILDREN WITH HODGKIN LYMPHOMA RECEIVING THE EURONET PROTOCOL
por: Bekhit, Hala, et al.
Publicado: (2023)

PB2402: CLINICAL CHARACTERISTICSAND PROGNOSIS RISK FACTORS OF NON-HODGKIN’S LYMPHOMA INVOLVING THE HEART
por: Chen, Yue, et al.
Publicado: (2023)

Second Cancers in Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma: A Systematic Review by the Fondazione Italiana Linfomi
por: Nassi, Luca, et al.
Publicado: (2022)

Hodgkin Reed–Sternberg-Like Cells in Non-Hodgkin Lymphoma
por: Parente, Paola, et al.
Publicado: (2020)

PB2063: CHARACTERISTICS AND THERAPEUTIC RESULTS OF PATIENTS WITH REFRACTORY/RELAPSED HODGKIN LYMPHOMA IN A TUNISIAN CENTER
por: Kammoun, F., et al.
Publicado: (2022)

PB2065: IMPORTANCE OF PET AS A PROGNOSTIC MARKER IN TREATMENT STRATEGY CHOICE IN PATIENTS WITH HODGKIN LYMPHOMA
por: Novosad, O., et al.
Publicado: (2022)

PB2257: OUTCOME AND PROGNOSTIC FACTORS OF PEDIATRIC PATIENTS WITH HODGKIN LYMPHOMA: A SINGLE-CENTER EXPERIENCE
por: Ali, Nesreen, et al.
Publicado: (2023)

PB2254: TREATMENT OUTCOME AND PROGNOSTIC FACTORS IN CHILDREN AND ADOLESCENTS WITH RELAPSED AND REFRACTORY CLASSIC HODGKIN LYMPHOMA
por: Ali, Nesreen, et al.
Publicado: (2023)

PB2316: SAFETY AND EFFICACY OF AUTOLOGOUS HSCT IN NINE PATIENTS WITH AIDS-RELATED NON-HODGKIN LYMPHOMA
por: Liu, Jun, et al.
Publicado: (2023)

PB2066: THE STUDY OF GSTP1 AND MDR1 GENES POLYMORPHISMS IN HODGKIN’S LYMPHOMA AND THEIR LINK WITH CHEMOTHERAPY RESPONSE.
por: Voytko, M., et al.
Publicado: (2022)

PB2322: MULTIPLE PRIMARY TUMORS IN PATIENTS WITH NON-HODGKIN’S LYMPHOMA: A RETROSPECTIVE SINGLE-CENTER STUDY
por: Sahakyan, Lusine, et al.
Publicado: (2023)

PB2415: THE ROLE OF NUTRITIONAL SUPPORT DURING AUTOLOGOUS STEM CELL TRANSPLANTATION (AUTOHSCT) IN PATIENTS WITH HODGKIN LYMPHOMA.
por: Volchenkov, Stanislav, et al.
Publicado: (2023)

PB2259: THE NEW PD-1 INHIBITOR PROLGOLIMAB IN THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN’S LYMPHOMA
por: Semenova, Anastasia, et al.
Publicado: (2023)

PB2260: FIVE-YEAR SINGLE-CENTER EXPERIENCE IN THE TREATMENT OF ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA WITH ABVD
por: Vukovic, Vojin, et al.
Publicado: (2023)

PB2277: PROGNOSTIC SIGNIFICANCE OF SERUM MONOCLONAL PROTEINS BASED ON IMMUNOFIXATION ELECTROPHORESIS IN B CELL NON-HODGKIN LYMPHOMA
por: Gao, Yuyang, et al.
Publicado: (2023)

Divergent clonal evolution of a common precursor to mantle cell lymphoma and classic Hodgkin lymphoma
por: Tashkandi, Hammad, et al.
Publicado: (2019)

PB1880: A MULTICENTER PHASE 1 STUDY EVALUATING THE SAFETY AND TOLERABILITY OF HMPL-760 IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA OR OTHER NON-HODGKIN LYMPHOMA
por: Kahl, B., et al.
Publicado: (2022)

PB2089: ALGORITHM FOR SEVERE COVID-19 RISK STRATIFICATION DEPENDING MONOCLONAL ANTI-CD20 ANTIBODIES TREATMENT DURATION IN NON-HODGKIN LYMPHOMA PATIENTS.
por: Sychevskaya, K., et al.
Publicado: (2022)

Body Composition Change, Unhealthy Lifestyles and Steroid Treatment as Predictor of Metabolic Risk in Non-Hodgkin’s Lymphoma Survivors
por: Daniele, A., et al.
Publicado: (2021)

PB1949: ROLE OF LAIR1 (CD305) IN FLOW CYTOMETRIC DETECTION OF OCCULT BONE MARROW INVOLVEMENT IN NON-CLL B-CELL NON-HODGKIN LYMPHOMA
por: Ghogale, Sitaram, et al.
Publicado: (2023)

PB2078: A RETROSPECTIVE ANALYSIS OF THE EFFICACY OF LOW-DOSE METRONOMIC CYCLOPHOSPHAMIDE FOR TREATMENT IN PATIENTS WITH LOW GRADE NON-HODGKIN LYMPHOMA
por: Han, B., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_v02ksidcbgkgtmaoquj32nn3q7